PT2770997T - Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico - Google Patents

Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico

Info

Publication number
PT2770997T
PT2770997T PT128439494T PT12843949T PT2770997T PT 2770997 T PT2770997 T PT 2770997T PT 128439494 T PT128439494 T PT 128439494T PT 12843949 T PT12843949 T PT 12843949T PT 2770997 T PT2770997 T PT 2770997T
Authority
PT
Portugal
Prior art keywords
heterocyclylbenzyl
isoindolin
analogs
substituted
acetylcholine receptor
Prior art date
Application number
PT128439494T
Other languages
English (en)
Inventor
W Lindsley Craig
Jeffrey Conn P
R Wood Michael
R Hopkins Corey
J Melancon Bruce
S Poslusney Michael
W Engers Darren
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of PT2770997T publication Critical patent/PT2770997T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT128439494T 2011-10-28 2012-10-28 Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico PT2770997T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161553121P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
PT2770997T true PT2770997T (pt) 2016-12-01

Family

ID=48168630

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128439494T PT2770997T (pt) 2011-10-28 2012-10-28 Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico

Country Status (10)

Country Link
US (4) US9586964B2 (pt)
EP (3) EP3639823A1 (pt)
AU (3) AU2012328476B2 (pt)
CA (1) CA2853826C (pt)
DK (1) DK2770997T3 (pt)
ES (1) ES2604958T3 (pt)
HU (1) HUE031313T2 (pt)
PL (1) PL2770997T3 (pt)
PT (1) PT2770997T (pt)
WO (1) WO2013063549A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2770997T3 (en) 2011-10-28 2016-12-19 Univ Vanderbilt SUBSTITUTED 2- (4-HETEROCYCLYLBENSYL) isoindolin-1-ON-ANALOGS AS POSITIVE allosteric modulators OF THE muscarinic acetylcholine receptor M1
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015080904A1 (en) * 2013-11-27 2015-06-04 Vanderbilt University Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
RS60524B1 (sr) 2014-04-23 2020-08-31 Takeda Pharmaceuticals Co Derivati izoindolin-1-ona kao pozitivni alosterni modulator aktivnosti holinergičkog muskarinskog m1 receptora za lečenje alzheimer-ove bolesti
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2016172547A1 (en) * 2015-04-24 2016-10-27 Vanderbilt University Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1
US9987242B2 (en) 2015-05-05 2018-06-05 Northwestern University Treatment of Levodopa-induced Dyskinesias
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017123482A1 (en) * 2016-01-14 2017-07-20 Merck Sharp & Dohme Corp. Dihydropyrido quinazoline m1 receptor positive allosteric modulators
WO2018089546A1 (en) * 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018226545A1 (en) 2017-06-09 2018-12-13 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
MA50806A (fr) * 2017-11-23 2020-09-30 Suven Life Sciences Ltd Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
PL3762368T3 (pl) 2018-03-08 2022-06-06 Incyte Corporation ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US20210355114A1 (en) * 2018-10-24 2021-11-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
GB201818348D0 (en) 2018-11-12 2018-12-26 Syngenta Participations Ag Herbicidal compounds
GB201818349D0 (en) 2018-11-12 2018-12-26 Syngenta Participations Ag Herbicidal compounds
TW202128161A (zh) 2019-10-18 2021-08-01 美國加利福尼亞大學董事會 用於靶向病原性血管之化合物及方法
EP4196473A1 (en) * 2020-08-13 2023-06-21 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP2024515597A (ja) * 2021-04-13 2024-04-10 コンティニューム・セラピューティクス・インコーポレイテッド ムスカリン性アセチルコリンm1受容体アンタゴニストの結晶性化合物
WO2022221556A1 (en) * 2021-04-14 2022-10-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2023086521A1 (en) * 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
WO2024086569A1 (en) * 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024086570A1 (en) * 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340701C (en) 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers
DE10042093A1 (de) * 2000-08-26 2002-03-07 Dresden Arzneimittel Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
EP1963271B1 (en) 2005-12-05 2010-07-28 Merck Sharp & Dohme Corp. Quinolone m1 receptor positive allosteric modulators
JP2009526044A (ja) 2006-02-07 2009-07-16 アストラゼネカ・アクチエボラーグ 新規な化合物i
US8178667B2 (en) 2006-06-28 2012-05-15 Merck Sharp & Dohme Corp. Benzyl-substituted quinolone M1 receptor positive allosteric modulators
WO2009026248A2 (en) * 2007-08-17 2009-02-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Hydrazide, amide, phthalimide and phthalhydrazide analogs as inhibitors of retroviral integrase
AU2009215111A1 (en) 2008-02-13 2009-08-20 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
JP2011530602A (ja) * 2008-08-12 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション N−ヘテロ環式m1受容体ポジティブアロステリックモジュレーター
JP2012505899A (ja) * 2008-10-16 2012-03-08 シェーリング コーポレイション アジン誘導体およびそれの使用方法
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
BR112012001532A2 (pt) 2009-07-23 2019-09-24 Univ Vanderbilt "substituída azolesulfonamides benzoimid e indolesulfonamides substituído como potenciadores mglur4"
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011163280A1 (en) 2010-06-21 2011-12-29 Vanderbilt University Indole compounds as positive allosteric modulators of the muscarinic receptor
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
DK2770997T3 (en) 2011-10-28 2016-12-19 Univ Vanderbilt SUBSTITUTED 2- (4-HETEROCYCLYLBENSYL) isoindolin-1-ON-ANALOGS AS POSITIVE allosteric modulators OF THE muscarinic acetylcholine receptor M1
WO2013071201A1 (en) 2011-11-11 2013-05-16 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US8697888B2 (en) 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
US9012445B2 (en) 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors

Also Published As

Publication number Publication date
AU2017204409A1 (en) 2017-07-20
EP3153167B1 (en) 2019-10-02
EP3153167A1 (en) 2017-04-12
EP2770997A1 (en) 2014-09-03
AU2012328476A1 (en) 2014-05-22
US20170129889A1 (en) 2017-05-11
CA2853826A1 (en) 2013-05-02
US20180179205A1 (en) 2018-06-28
AU2019200952A1 (en) 2019-02-28
US10654847B2 (en) 2020-05-19
DK2770997T3 (en) 2016-12-19
ES2604958T3 (es) 2017-03-10
AU2012328476B2 (en) 2017-03-30
EP2770997B1 (en) 2016-09-14
AU2017204409B2 (en) 2018-11-15
US20140288084A1 (en) 2014-09-25
HUE031313T2 (hu) 2017-07-28
PL2770997T3 (pl) 2017-05-31
US20200231592A1 (en) 2020-07-23
CA2853826C (en) 2021-03-23
AU2019200952B2 (en) 2020-07-16
WO2013063549A1 (en) 2013-05-02
US9586964B2 (en) 2017-03-07
EP3639823A1 (en) 2020-04-22
EP2770997A4 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
PL2770997T3 (pl) Podstawione analogi 2-(4-heterocyklilobenzylo)izoindolin-1-onu jako pozytywne allosteryczne modulatory receptora muskarynowego M1 acetylocholiny
EP2817295A4 (en) SUBSTITUTED 5-AMINOTHIENO- [2,3-C-] PYRIDAZINE-6-CARBOXAMIDANALOGA AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINACETYLCHOLIN RECEPTOR M4
HK1201737A1 (en) Muscarinic m1 receptor agonists
EP2588104A4 (en) POSITIVE ALLOSTERIC MODULATORS OF ISOINDOLONE M1 RECEIVER
HK1205114A1 (en) Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents
HRP20180913T1 (hr) Pozitivni alosterni modulatori receptora nikotinskog acetilkolina
HK1191330A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5 mglur5
HK1195298A1 (zh) 作為 變構調節劑的乙炔基衍生物
HK1203938A1 (en) Novel 2h-indazoles as ep2 receptor antagonists ep2 2h-
EP2709451A4 (en) POSITIVE ALLOSTERIC N-NETWORKED LACTAM M1 RECEPTOR MODULATORS
EP2563126A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR DERIVED FROM HETEROCYCLIC QUINOLIZINE
EP2709621A4 (en) POSITIVE ALLOSERIC MODULATORS OF M1 RECEPTOR TO QUINOLINE-AMIDE N-BINDING
EP2796459A4 (en) NEW S1P RECEIVER MODULATOR
IL250286A0 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
EP2809156A4 (en) 5-HYDROXYTRYPTAMINE (5HT2CR) 2C RECEPTOR 2C ALLOSTERIC MODULATORS
HK1216095A1 (zh) 烟碱乙酰胆碱受體的新的正向別構調節劑
EP2768814A4 (en) NOVEL NON-STEROID COMPOUNDS AS MODULATORS OF AN ANDROGEN RECEPTOR
HK1259310A1 (zh) 烟碱乙酰膽碱受體的正變構調節劑